Takeda Pharmaceutical (TAK) Research & Development (2017 - 2026)

Takeda Pharmaceutical's Research & Development history runs 10 years deep, the most recent figure standing at $7.4 billion for Q1 2026.

• On a quarterly basis, Research & Development fell 9.59% year-over-year to $7.4 billion in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 13.24% decrease from a year earlier, with the FY2026 full-year figure at $4.5 billion, down 6.33% from the prior year.
• Research & Development climbed to $7.4 billion in Q1 2026 per TAK's latest filing, from -$1.1 billion in the prior quarter.
• Across five years, Research & Development topped out at $8.5 billion in Q1 2024 and bottomed at -$1.3 billion in Q3 2023.
• The 5-year median for Research & Development is -$1.1 billion (2024), against an average of $458.6 million.
• Across the five-year window, Research & Development plunged 116.38% in 2022 and surged 793.43% in 2024, its largest moves.
• Year by year, Research & Development stood at -$1.2 billion in 2022, then slipped by 2.56% to -$1.3 billion in 2023, then rose by 11.69% to -$1.1 billion in 2024, then fell by 1.71% to -$1.1 billion in 2025, then jumped by 747.68% to $7.4 billion in 2026.
• Per Business Quant, the three latest TAK Research & Development figures stand at $7.4 billion (Q1 2026), -$1.1 billion (Q4 2025), and -$1.1 billion (Q3 2025).